2026-01-22 - Analysis Report
## REGN: Comprehensive Analysis

### Company Overview
Regeneron Pharmaceuticals, Inc. (REGN) is a biopharmaceutical company involved in the discovery, development, and commercialization of pharmaceutical products for various medical conditions.

### Return Rate Comparison

* Cumulative return of REGN: 28.13%
* Cumulative return of S&P 500 (VOO): 91.55%
* Divergence: -63.42% (calculated from provided -67.90 and 91.55)
* Relative divergence: 20.10%

### Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | -14.0% | 22.4% | -19.0% | 1.2 | 39.6B |
| 2017-2019  | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B |
| 2018-2020  | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B |
| 2019-2021  | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B |
| 2020-2022  | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B |
| 2021-2023  | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B |
| 2022-2024  | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B |
| 2023-2025  | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B |

### Stock Price Fluctuations

* Close: $749.33
* Last-market: $749.33 (change: +$2.12)
* 5-day SMA: $742.44
* 20-day SMA: $771.23
* 60-day SMA: $726.51

### Indicator Analysis

* Market Risk Indicator (MRI): 0.80
* RSI: 42.50
* PPO: -1.02
* Expected Return (%): -48.00%
* Recent relative divergence change: -8.10 (-): worsening

### Recent News & Significant Events
[See list below for recent news headlines]

[2026-01-21] 40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan (news.google.com)
[2026-01-21] YieldBoost REGN From 0.5% To 5.6% Using Options - Nasdaq (news.google.com)
[2026-01-06] REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Yahoo Finance (news.google.com)
[2026-01-18] Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat (news.google.com)
[2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative (news.google.com)
[2026-01-18] Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st (news.google.com)

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 825.23 / 1057.00 / 630.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|----:|----:|--------|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

### Financial Information

#### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

#### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

### Comprehensive Analysis
Based on the provided data, REGN has a relatively stable stock price, with a cumulative return of 28.13% compared to the S&P 500's 91.55%. However, the divergence is significant, and the relative divergence indicates a relatively stable position within the fluctuation range.

The alpha, beta analysis indicates that REGN has had varying performances across different time periods, with some periods showing strong negative returns and others showing moderate returns.

The stock price fluctuations over the past 5, 20, and 60 days show that the stock price is currently above its moving averages, indicating a possible upward trend.

The indicator analysis shows a bearish trend, with the RSI and PPO indicators indicating oversold conditions, and the expected return is negative.

The analyst opinions indicate a slightly positive sentiment, with a mean rating of 1.69 (~Buy) and a target price of 825.23.

The recent earnings analysis shows a relatively strong EPS and revenue growth over the past year.

Overall, the comprehensive analysis suggests that REGN may be a relatively stable investment opportunity, but with some caution due to the bearish trend and negative expected return.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.